BloomMD review

The treatment title is more useful than the old page address

BloomMD’s current semaglutide page starts at $199 per month; its compounded tirzepatide page starts at $279. Both expanded detail panels direct dose, supply and final payment choices to the questionnaire. An older semaglutide page address mentions a ten-week vial, but the current offer does not turn that address into a quoted supply term. ^{[1] [2]}

Obtain the actual prescribed preparation and program period before comparing the initial payment. These pages name compounded products. They do not sell a branded drug merely because the active ingredient also appears in a brand-name treatment, and a price from a separate microdose or branded listing should not be substituted.

Compare actual first and continuing payments with the GLP-1 complete-cost planner.

Availability needs resolving before the recurring purchase

Both current product pages say the online intake is being prepared for launch. They direct prospective patients to the team for availability, while making treatment conditional on history, eligibility, provider review and state access. A published starting price is not confirmation that a specific new-patient pathway can be completed today. ^{[1] [2]}

BloomMD describes individual provider review and portal follow-up. Its FAQ calls the service self-pay and routes refills or treatment changes to the prescribing team. Confirm the current enrollment route, responsible clinician and follow-up arrangement before moving existing care or assuming that a low headline includes every clinical charge. ^[3]

For a separate package-total and quarterly-billing comparison, read our PeterMD package review.

For a different account-based care model and purchase agreement, compare our Arc-1 care-and-purchase review.

A compounded prescription requires its own product decision

The product pages state that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. That disclosure matters more than a shared ingredient name or an encouraging customer review. A trial involving a branded preparation does not establish the same outcome for every compounded prescription. ^{[1] [2] [6]}

The selected formulation, dispensing pharmacy and clinical reason for compounding belong in the actual care discussion. Compare service access and complete cost without treating the site’s supplement suggestions as required medication support. An optional retail product needs its own reason to earn a place in the budget.

Keep the tested preparation and population visible in the semaglutide-versus-tirzepatide research.

Separate the billing deadline from an eligibility refund

The subscription policy requires cancellation at least seven days before the next billing cycle; it makes the billed cycle nonrefundable. Dispensed prescriptions cannot be returned, and personalized services already rendered are nonrefundable. Confirm whether the selected order recurs and obtain the processing calendar before paying. ^[4]

The shipping policy separately describes a product refund when a provider finds a patient ineligible. That condition does not create a general post-dispensing return right. Prescription delivery charges also need their own quote: the FAQ excludes prescriptions from its $75 retail free-shipping threshold. Compare available services once these access and payment conditions are settled. ^{[3] [5]}

Separate the care relationship from fulfillment in our clinical-service and pharmacy-access comparison.

Understanding the cost

Advertised compounded-program starts: semaglutide $199/month; tirzepatide $279/month. Current pages say online intakes are being prepared for launch. Confirm current enrollment, actual prescription, supply, initial bill, shipping and selected recurring terms.